You are here

A Quantitative Optical Sensor to Monitor Tumor Vascular Physiology

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42CA156901-02A1
Agency Tracking Number: R42CA156901
Amount: $1,321,235.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: PA13-235
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-09-22
Award End Date (Contract End Date): 2016-08-31
Small Business Information
ZENALUX BIOMEDICAL, INC., Durham, NC, 27705-4596
DUNS: 781008490
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 JESKO VONWINDHEIM
 (919) 794-5757
 jesko@zenalux.com
Business Contact
 MARLEE JUNKER
Phone: (919) 794-5757
Email: marlee.junker@zenalux.com
Research Institution
 DUKE UNIVERSITY
 2200 W MAIN ST, SUITE 820
DURHAM, NC, 27705-4673
 Nonprofit college or university
Abstract
DESCRIPTION provided by applicant In there were new cases of head and neck cancers HNC in the United States Early detection of new and locally recurrent cancers is clinically important to reduce not only cancer related mortality but also treatment associated morbidity as it impacts multiple organ functions including respiration olfaction hearing eating swallowing and speaking Discrimination of cancer from non malignant tissues is dependent on pathological examination of lesion biopsies Although these lesions are identified during an initial clinical exam obtaining a specimen for analysis can be technically challenging and uncomfortable for patients Furthermore there is an immense amount of labor facility and monetary resources that are expended on patients who ultimately have no malignancy Once carcinoma is identified treatment for advanced HNC commonly requires a combination of surgery radiation and chemotherapy to maximize the chance for cure Multi modality treatment causes undesirable side effects that affect a patientandapos s physical well being e g eating and speaking and quality of life Using fewer modalities can minimize morbidity but with a potentially increased risk for treatment failure Determination of the optimal strategy to both minimize morbidity and optimize the chance for cure is a major clinical challenge There is a significant unmet clinical need associated with the screening and treatment of head and neck cancers Our long term goal is to develop a portable optical technology that can provide accurate and precise analysis of tissue absorption and scattering of local tissue sites guided by white light and auto fluorescence imaging The initial market will be applications related to the diagnosis and guided therapy of head and neck cancers The clinical value of this tool would require it to be fast and non invasive such that feedback could be obtained during the patientandapos s visit portable such that it can be used in an ambulatory setting and quantitative with minimal operator bias such that data obtained is consistent across operators and patients PUBLIC HEALTH RELEVANCE Our long term goal is to develop and commercialize a portable optical technology that can provide accurate and precise analysis of tissue absorption and scattering of local tissue sites guided by white light and auto fluorescence imaging for the diagnosis and guided therapy of head and neck cancers There is lack of a tool that can be routinely applied to assess diagnostically and therapeutically relevant endpoints in HNSCC therefore this grant is significantly related to public health for its potential to improve the diagnosis and treatment of HNSCC

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government